GET DAILY SIGNALSWhy Is Astrana Health (ASTH) Stock Down -13.07% Today?
Key Takeaways
- ASTH shares fell 13.07% to $33.91, extending a decline after the company's third-quarter earnings report.
- The primary catalyst was a third-quarter earnings report that missed consensus on the bottom line and raised fresh concerns about medical cost trends.
- Management flagged that Medicaid medical cost trend is running above assumptions, with early signs of adverse selection in its membership base.
- The company expects a 10–15% decline in Medicaid membership in 2027, creating a mid-single-digit headwind to EBITDA growth.
- Broader healthcare and value-based care sentiment compounded the selling pressure as investors reassessed near-term profitability.
- Traders are now watching for analyst rating changes and further clarity on the company's 2027 outlook.
- For additional context, explore Price Targets, Earnings, and Forecast pages for ASTH.
- Discover AI-powered trading strategies for this and other tickers on the Trending AI Robots page.
Opening Summary
Astrana Health, Inc. (ASTH), the Alhambra, California-based, physician-centric healthcare management company formerly known as Apollo Medical Holdings, saw its stock plunge 13.07% on Thursday, trading at $33.91 versus a prior close of $39.01. The selloff, which marked a decisive downward move for the value-based care operator, came as investors digested the company's third-quarter 2026 results and, more importantly, management's commentary on deteriorating Medicaid cost trends. While revenue held broadly in line with expectations, a bottom-line miss and a cautious 2027 outlook overshadowed otherwise solid operational momentum, triggering the sharp market reaction.
Earnings-Driven Move: A Bottom-Line Miss Weighs on Sentiment
The immediate catalyst for the decline was the company's third-quarter earnings report. Astrana Health posted revenue of approximately $1.02 billion, essentially in line with consensus, while adjusted EBITDA reached a record $77.2 million, up 13% year over year. However, GAAP earnings per share came in at $0.26, well below the roughly $0.44 consensus estimate, as higher stock-based compensation and increased net income attributable to non-controlling interests absorbed much of the quarter's profit improvement.
The earnings miss was compounded by the quality of the quarter. Management acknowledged that third-quarter results benefited from a non-recurring Medicare Shared Savings Program accrual and roughly $5 million to $10 million of risk-adjustment sweeps, items not expected to repeat in the seasonally weaker fourth quarter. That dynamic left investors questioning the sustainability of near-term profitability even as the headline EBITDA figure looked strong.
Medicaid Cost Trends and a Cautious 2027 Outlook
Beyond the headline numbers, the market reaction was driven by a notable shift in management's tone around medical cost trends. Medicaid medical cost trend, which had been described as favorable earlier in the year, is now running above initial assumptions, with management citing early signs of adverse selection as the risk profile of the remaining membership base ticks upward. Commercial cost trends were also flagged as slightly elevated, primarily due to clinician-administered drug costs.
The forward-looking commentary added to the pressure. Astrana Health said it now anticipates a 10% to 15% decline in Medicaid membership in 2027, which management expects to translate into a mid-single-digit headwind to EBITDA growth. The company also softened its medium-term EBITDA growth framing from "mid-to-high teens" to "at least mid-teens," while full-year guidance was narrowed around unchanged midpoints rather than raised. Together, these signals suggested a more challenging earnings trajectory than investors had priced in ahead of the report.
Market Context and Trading Activity
The decline unfolded with notable selling pressure as the stock, which had rallied into the print, gave back much of its recent gains. Astrana Health shares entered the report trading near the upper end of their recent range, leaving little room for disappointment, and the sharp reversal reflected a meaningful reassessment of positioning rather than isolated profit-taking. The move pushed the stock well below its 50-day moving average and highlighted the sensitivity of value-based care names to any deterioration in medical loss ratios and membership trends. While the selloff was company-specific in its catalysts, it also resonated with broader investor wariness around healthcare services stocks facing cost-trend and regulatory uncertainty.
What Comes Next for ASTH
Looking ahead, investors will be watching for updated analyst ratings and revisions to estimates in the wake of the earnings call. Key areas of focus include the trajectory of Medicaid membership and medical cost trend into 2027, the integration and synergy progress from the Prospect Medical acquisition, and the resolution of outstanding items such as the unsized September cybersecurity incident and the remediation of a disclosed material weakness in internal controls. The company's shift toward a higher mix of full-risk arrangements and its new Medicare Advantage partnerships, including one with Alignment Healthcare, offer potential upside, but the near-term risk profile has clearly shifted. Continued cost-trend deterioration, slower membership growth, or further guidance reductions would likely keep pressure on the shares, while stabilization in medical costs and clearer 2027 visibility could provide a basis for recovery.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots that are performing strongest under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, giving traders a way to explore data-driven approaches across a wide range of markets. To see which strategies are currently leading, visit the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ASTH in downward trend: price may drop because broke its higher Bollinger Band on November 04, 2026
ASTH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 50 similar instances where the stock broke above the upper band. In 42 of the 50 cases the stock fell afterwards. This puts the odds of success at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where ASTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ASTH as a result. In 68 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for ASTH just turned positive on November 04, 2026. Looking at past instances where ASTH's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
ASTH moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ASTH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTH advanced for three days, in 241 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 119 of 195 cases where ASTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ASTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.099) is normal, around the industry mean (203.977). P/E Ratio (42.878) is within average values for comparable stocks, (20.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.097) among similar stocks. P/S Ratio (0.485) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement